June 24, 2022 7:22am
No answers anytime soon for the questions on when will inflation peak, how soon will we see a recession, and how high will the Fed raise rates?
Pre-open indications, 2 Negative Indications, 4 SELLs into Strength and 1 Puff/Pump/Promote
RMi outlines a daily bell ringing of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.
Who is defining the metrics for investors and keeping you notified of the sector and market fluctuations? What I provide is a trusted source of share pricing intelligence – it’s more than opinion, I deal in the facts and numbers that back them up.
The 7:30 A.M., ET edition
Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.
Dow futures are UP +0.65% (+199 points), S&P futures are UP +0.74% (+28 points) and NASDAQ futures are UP +0.88% (103 points) early in the pre-open – so far,
Stock futures were up Friday anticipating a positive open,
European markets moved higher on Friday to end a volatile week,
Asia-Pacific markets were higher overnight, led by Hong Kong’s Hang Seng index and South Korea’s Kospi.
Henry’omics:
The Dow, Nasdaq and S&P 500 jumped on Thursday as bond yields slid weighing recession risks
Economic Data Docket: New home sales data is due out at 10 a.m. ET and the final University of Michigan consumer sentiment report for June will follow later in the day.
RegMed Investors’ (RMi) closing bell: “which way forward? SELL into Strength, come back post earnings. Five (5) positive sessions, 1 holiday out of seven (7) closing sessions; algorithms are lurking.” … https://www.regmedinvestors.com/articles/12485
Ebb and flow –
Q2/22 –
June – 9 positive and 7 negative closes
· May - 11 positive and 10 negative closes
· April - 1 holiday, 6 positive and 13 negative closes
Q1/22:
· March – 13 negative and 10 positive closes
· February stats: 11 negative, 8 positive closes and 1 holiday
· January stats: 2 holidays, 1 neutral, 13 negative and 6 positive closes
Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS
Negative Indications:
Verve Therapeutics (VERV) closed up +$2.08 to $16.18 after Thursday’s $1.07 with a negative -$0.45 or -2.78% pre-open indication,
Beam Therapeutics (BEAM) closed down -$2.44 to $41.57 with a negative -0.20 or -0.48% pre-open indication,
Sell into Strength:
Intellia Therapeutics (NTLA) closed up +$5.22 to $50.76 after Wednesday’s +$1.06 and Tuesday’s +$1.50 with a positive +$0.36 or +0.71% pre-open indication,
Alnylam Pharmaceuticals (ALNY) closed up +$4.74 to 4146.30 after Wednesday’s +$2.54 and Tuesday’s +$1.93 with a negative -$0.15 or -0.10% pre-open indication,
Beam Therapeutics (BEAM) closed up +$2.44 to $41.57 after Wednesday’s +$1.08 and Tuesday’s +$2.28 with a negative -$0.20 or -0.48% pre-open indication,
Fate Therapeutics (FATE) closed up +$2.00 to $25.61 after Wednesday’s +$11.38 and Tuesday’s +$1.19 with a negative -$0.78 or -3.05% pre-open indication,
Puff/Pump and Promote: Maintaining SELL
Biostage (OTCQB: BSTG) closed -$0.09 on Thursday following Wednesday $0.00 after Tuesday’s +$0.09 with 467 shares traded.
WARNING: Earnings reported a VERY SAD picture of a company’s status without U.S investors and reliance on non-U.S. Chinese investors.
BSTG filed a new 8-K re Harvard BIOSCIENCE (HBIO) and in lieu of cash payment < https://app.quotemedia.com/data/downloadFiling?webmasterId=101533&ref=116769338&type=HTML&formType=8-K&dateFiled=2022-06-13&cik=0001563665&CK=1563665&symbol=0001563665&companyName=Biostage >
BSTG seems to always finagling a finagle and NOTHING is CLEAN and STRAIGHTFORWARD.
- is it the ONLY avenue to finance utilizing non-U.S. Chinese investors?
- WATCH and be ready for a BIG reverse of shares to enable offering from multiple private placements
The BOTTOM LINE: Markets have bid up most cell and gene therapy equities without much if any news.
There will be a few pick-up stocks – remember, the month and quarter are coming to a close – earnings are coming …
Investors may want to at least consider taking partial profits – when they can; we are approaching earnings season, no sooner did we finish than we start again.
I STILL haven’t heard the bugle sound of a sustainable advance or rally … rising rates and slowing economic growth are not a supportive environment for investors.
This continuing state of volatility confirms fears that I have been expressing in these daily and weekly posts.
I have NOT seen ANY step-up of declining company investments by ANY CEOs and their management teams – WHY NOT?
I try to keep it simple … and short!
There is VALUE out there however, it’s about playing or betting the timing of the sector.
We are left with choosing to hang on to “our” portfolio position as it is a given that the sector shifts from fierce, sudden sell-offs to gaining altitude or ascending not to its value but, better than it was.
Whether information or intelligence is good, bad or somewhere in between; RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
All investments are subject to risks. Investors should consider investment objectives.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.
